top of page

When the Data Is Trying to Tell You Something: Compliance Lessons from Skin Substitutes

Writer: Jessica Zeff
Jessica Zeff
Oct 25
3 min read

The skin-substitute story is about much more than wound care. It demonstrates why compliance programs need to look beyond whether individual claims are technically correct, and what can happen when lucrative reimbursement, rapidly increasing utilization, clinical discretion and financial incentives converge.


Medicare spending on skin substitutes increased 640% in just two years, reaching more than $10 billion in 2024. Spending per beneficiary tripled, and home-based care ultimately accounted for more than half of Medicare Part B spending on skin substitutes.


Those trends drew the attention of OIG, CMS and DOJ, leading to increased scrutiny, payment reform, enforcement actions, audits and recoupments.


For compliance professionals, the more fundamental question is:


Would your compliance program have recognized the warning signs before the government did?


The warning signs regulators identified: rapid growth, unusual utilization, financial incentives and aberrant billing patterns, were visible in the data.


Healthcare organizations have data too.


Follow the Money, but Also Follow the Behavior


Before 2026, Medicare generally reimbursed skin substitutes as biological products. When Average Sales Price (ASP) data was unavailable, reimbursement could instead be based on Wholesale Acquisition Cost (WAC) or invoice pricing.


OIG found that products without ASP-based payment amounts could create a larger spread between what providers paid and what Medicare reimbursed. Its analysis suggested providers could switch to newer products still reimbursed using WAC or invoice pricing after ASP pricing became applicable to other products.


From a compliance perspective, the important question isn't simply whether the reimbursement was permissible. It's whether the reimbursement structure was influencing behavior.


That distinction matters well beyond wound care.


Whenever one product, service, procedure, site of service or billing methodology produces significantly greater reimbursement than another, compliance should understand the incentive that creates. It doesn't mean the resulting care is inappropriate, but it may mean the activity warrants monitoring.


Compliance programs should be asking:


Where are the financial incentives in our business, and what behavior might they encourage?


Don't Just Audit Claims. Audit Patterns.


Traditional billing audits typically examine a sample of claims for coding, documentation, medical necessity and billing compliance. That's important, but it isn't enough.


OIG identified patterns involving skin substitutes that included treatment without prior conservative care, providers billing primarily for skin substitutes rather than other wound-care services, high volumes of same-day claims, excessive quantities, non-approved uses, and clinicians outside traditional wound-care specialties billing for the procedures.


Those aren't necessarily problems you find by reviewing individual claims. They're patterns.


Compliance monitoring should therefore ask questions such as:


  • Who are the highest-volume providers?

  • Has utilization changed significantly?

  • Is one clinician using substantially more of a product than peers?

  • Are certain patients receiving significantly more services?

  • Are quantities or treatment durations increasing?

  • Did utilization change after reimbursement changed?


This doesn't require sophisticated artificial intelligence. Straightforward trending and comparative reports can tell compliance where to look more closely.


Consider one of the enforcement examples: DOJ alleged approximately $205 million in Medicare claims associated with skin substitutes furnished by one nurse practitioner to roughly 120 patients.


Whatever the service line, numbers that differ dramatically from what would ordinarily be expected deserve attention.


What Should Compliance Programs Do?


Organizations don't need to wait for an OIG report naming their service line before examining their own risk. Practical steps include:


Trend utilization. Look at services, products, providers, locations and patients over time rather than relying exclusively on isolated claim samples.


Identify and investigate outliers. Being an outlier doesn't mean someone has done something wrong. It means there may be a reason to understand why the data looks different.


Connect clinical, billing and purchasing information. If reimbursement is affected by acquisition cost, discounts, rebates, product selection or clinical utilization, compliance needs visibility across those functions.


Audit medical necessity, not merely documentation. A well-documented service is not necessarily medically necessary. Determine whether the record supports why the treatment was appropriate and whether applicable prerequisites were met.


Use regulatory intelligence to drive the audit plan. OIG reports, CMS announcements, enforcement actions, contractor guidance and payment-policy changes shouldn't simply become compliance-news emails. They should prompt the question: Do we have this risk?


The Data May Be Giving You an Early Warning


Healthcare enforcement increasingly begins with data. Government agencies and contractors can identify providers whose billing differs from their peers, services experiencing extraordinary growth, unusual utilization patterns, and relationships between reimbursement and provider behavior.


Healthcare organizations have access to much of that same information about themselves.


The goal isn't to predict the next enforcement action. It's to recognize when your own data is giving you a reason to ask questions, before someone outside the organization asks them for you.

Comments


bottom of page